April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Visual Outcomes After Wavefront-guided Laser in situ Keratomileusis With and Without Iris Registration in Hyperopia
Author Affiliations & Notes
  • T. L. Purcell
    Ophthalmology, UCSD Shiley Eye Center, La Jolla, California
  • S. Chimsuntorn
    Ophthalmology, UCSD Shiley Eye Center, La Jolla, California
  • A. Torres
    Ophthalmology, UCSD Shiley Eye Center, La Jolla, California
  • T. Tantayakom
    Ophthalmology, Pramongkutklao Hospital, Bangkok, Thailand
  • D. J. Schanzlin
    Ophthalmology, UCSD Shiley Eye Center, La Jolla, California
  • Footnotes
    Commercial Relationships  T.L. Purcell, None; S. Chimsuntorn, None; A. Torres, None; T. Tantayakom, None; D.J. Schanzlin, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 552. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. L. Purcell, S. Chimsuntorn, A. Torres, T. Tantayakom, D. J. Schanzlin; Visual Outcomes After Wavefront-guided Laser in situ Keratomileusis With and Without Iris Registration in Hyperopia. Invest. Ophthalmol. Vis. Sci. 2009;50(13):552.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate and compare the efficacy, safety, predictability of wavefront-guided laser in situ keratomileusis (LASIK) in hyperopic patients in which iris registration (IR) was used and eyes in which iris registration would not engage (no-IR group) at 3 and 6 months.

Methods: : This retrospective study included 58 eyes of 31 patients with primary hyperopia or hyperopic astigmatism. Twenty- two eyes were in the IR group and 36 in the no -IR group. Both had comparable baseline characteristics. The mean preoperative spherical equivalent was 1.69±0.84 D and 1.81±0.72 D in IR and no-IR group respectively (P = 0.876). All eyes were done using the Visx Custom Vue S4 IR platform (Advanced Medical Optics). Safety, efficacy, predictability and need for enhancement were compared in both groups at 3 and 6 months.

Results: : Safety was evaluated at 3 months. There was 73% in the IR 83% in no-IR group that had the same best spectacle-corrected visual acuity (BSCVA) as preoperatively or had gained 1 or 2 lines of BSCVA. No eye in either group lost more than 1 line of BCVA (P = 0.505).Efficacy was also evaluated at 3 months. There was 45% in the IR and 61% in the no-IR group that had the same uncorrected visual acuity (UCVA) as preoperatively or had gained 1 or 2 lines of UCVA. No eye in either group lost more than 1 line of UCVA (P = 0.285). No enhancements were performed.Safety was evaluated at 6 months. There was 91% in the IR group and 86% in the no-IR group that had the same BSCVA as preoperatively or had gained 1 or 2 lines of BSCVA. No eye in either group lost more than 1 line of BCVA (P = 1.000).Efficacy was also evaluated at 6 months. There was 68% in the IR and 72% in the no-IR group that had the same UCVA as preoperatively or had gained 1 or 2 lines of UCVA. No eye in either group lost more than 1 line of UCVA (P = 1.000). Enhancements were done in 9% in the IR and 4% in the no-IR group.

Conclusions: : The results in both the IR and no-IR hyperopic patients were comparable with good refractive measured outcomes at both 3 and 6 month follow-ups. There were no statistically significant differences between both groups.

Keywords: refractive surgery: LASIK • hyperopia • refractive surgery: comparative studies 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×